ORALLY GIVEN CHEMO-ENDOCRINE THERAPY FOR PATIENTS WITH LUMINAL Her-2/neu NEGATIVE METASTASING BREAST CANCER
Keywords:
metastasing luminal Her-2/neu negative breast cancer, palliative cytostatic therapy, concurrent chemo-endocrine therapy, progressionfree period, tegafur, anastrozole.Abstract
Summary. Aim: optimize the treatment of patients with
hormone-positive (luminal) Her-2/neu negative metastasing breast cancer (MBC) through the taking endocrinoand chemotherapeutical drugs orally on an outpatient basis. Object and methods: the results of treatment of 80 patients with luminal Her-2/neu negative MBC, who were
randomized into 2 groups and treated with chemotherapy
and endocrinotherapy that were given only per os. The first
group (A) consisted of patients who had palliative hormone
therapy with aromatase inhibitor anostrozol (1 mg daily).
Conventionally 1 course of therapy in this group believed
interval of 21 days. The second group (A + T) formed with
patients who appointed concurrent hemoendocrinotherapy:
tegafur (1200–1600 mg/day, from the 1st to the 14th day of
the 21-day cycle) in combination with a daily intake anastrozol (1 mg). Treatment was performed to signs of tumor
progression or occurrence of side effects toxicity grade III–
IV. We determined the duration of progression-free period (time from start of treatment within the study to detect
signs of progression against the background of the treatment), survival (by Kaplan — Meier method); toxic manifestations therapy was assessed by questionnaire patients.
Results: length medium period without progression in patients of group A+T was longer for such in groupA (14.0±
2.4 to 9.2 ± 1.0 months, p < 0.05). Progression-free survival was significantly higher in patients treated with concurrent chemotherapy with endocrinotherapy, compared
with that of patients who received monoendocrinotherapy
(log-rank test, χ2 = 3.8369, p = 0.012). 10% of patients in
group A + T managed to achieve long period without progressive (> 24 months) without occurrence of adverse events
grade III–IV. The frequency of side effects in patients taking different types of palliative therapy orally was almost
the same in both study groups: 98.7% of patients were toxicity grade I and II. Conclusion: palliative treatment given
orally for patients with luminal Her-2/neu negative MBC
using antimetabolites tegafur and non-steroidal aromatase inhibitor anastrozole— demonstrates sufficient efficacy, the possibility of prolonged use, minor side effects; positively perceived by patients with advanced tumor process.
References
NCCN Clinical Practice guindlines in oncology. Breast cancer. Version 2.2015 (http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp).
Cesar AS, Gradishar WJ. Changing treatment paradigms inmetastatic breast cancer. Jama Oncol 2015; 1 (4): 528–34.
Debled M, Madrangues N, Trainaud A, et al. First-line Capecetabine monotherapy for slowly progression metastatic breast cancer. Do we need aggressive treatment? Oncology 2009; 77: 318–27.
Sitzia J, Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract 1998; 6 (1): 13–21.
Манзюк ЛВ, Артамонова ЕВ, Сатирова ЕФ, АлаторцеваЕС. Оригинальная комбинация Фторафур+ Винорельбин влечении рака молочной железы: первые результаты. Совр онкол 2012; 1 (12): 56–9.
Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-flioracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7 (4): 288–323.
Wright J, Prigot A, Wright BP. An evaluation of folic acid antagonists in adults with neoplastic diseases. Astudy of 93 patients with incurable neoplasms. J Natl Med Assoc 1951; 43: 211–40.
History of cancer chemotherapy (https://en.wikipedia.org/wiki/ History_of_cancer_chemotherapy).
Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–33.
Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294 (8): 405–10.
Coates AS, Winer EP, Goldhirsc A, et al. Tailoring therapies — improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; doi: 10.1093/annonc/mdv221.
Roy SS, Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012; Article ID 654698: 8 (http://dx.doi.org/10.1155/2012/654698).
Charalambous Ch, Pitta ChA, Constantinou AI. Equol enhances tamoxifen’s anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer 2013; 13: 238. doi:10.1186/1471–2407–13–238.
Altundaga K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 2006; 11 (6): 553–62.
Mouridsen H, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol 2003; 4 (14): 33–45.
Kaufmann M, Bajetta E, Dirix LY, et al.Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized doubleblind trial. J Clin Oncol 2000; 18: 1399–411.
Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471–7.
Australian and New Zealand Breast Cancer Trials Group. Arandomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 1986; 4: 186–93.
Bezwoda WR, Derman D, De Moor NG, et al. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. Cancer 1982; 50: 2747–50.
Sledge Jr GW, Hu P, Falkson G, et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group Study. JCO 2000; 18 (2): 262–8.
Bedognetti D, Sertol M, Prozato P, et al.Concurent vs sequential adjuvant chemotherapy and hormone therapy inbreast cancer: amulticenter randomized phaseIII trial. J Natl Cancer Inst 2011; 103: 1529–39.
Ibrahim NK, Yariz KO, Bondarenko I, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011; 17: 6822–30.
Torrisi R, Dellapasqua S, Ghisini R, et al. Preoperative concurrent chemo- and endocrine therapy for women with large operable breast cancer expressing steroid hormone receptors. Breast 2009; 17: 654–60.
Watanabe N. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients. Breast Cancer 2009; 17(4): 247–53.
Mohammadianpanah M, Ashour Y, Hoseini S, et al. The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trials. Breast Cancer Res Treat 2011; 132 (3): 853–61.
Тимовская ЮА, Зотов АС. Химиоэндокринотерапия при распространенном раке грудной железы. Клин онкол 2015; 3 (19): 1–7.
Eisenhauer EA, Therasse PT, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer 2009; 45: 228–47.
Cancer therapy evaluation program, common terminoligy criteria for adverse events, version 3.0. DCTD, NCI, NIH, DHHS 2003 (http://ctep.cancer.gov).
Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11 (4): 325–35.
Ishizuna K, Ninomiya J, Ogawa T, et al.Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: asingle-center retrospective study. Gan To Kagaku Ryoho 2014; 41 (13): 2577–82.
Kajanti MJ, Pyrhönen SO, Maiche AG. Oral tegafur in the treatment of metastatic breast cancer: a phase II study. Eur J Cancer 1993; 29A (6): 863–6.
Nabholtz JM, Buzdar A, Pollac M, et al. Anastrazole is superior to tamoxifen as first line therapy for advanced breast cancer in post menopausal women, result of aNorth American Multicenter Randomized Trial. J Clin Oncol 2000; 18: 3758–46.
Buzdar AU. Advances in endoctine treatment for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8 (4): 335–41.
Jain KK. Drug-induced neurological disorders. 3rd revised and explained edition. Basen: Hogrefe publishing, 2012. 476 p.
